New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who ...

US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of ...

A new building of condominiums — including three affordable units — has been proposed for Brighton Center. Biotech's Future - ...

He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the multibillion-dollar commercial drugmaker it is today. Taking his place at the helm is Bill ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Denali Therapeutics remains an intriguing clinical-stage biotech focused on neurodegenerative and lysosomal storage diseases.